Table 3 Clinical trials of extracellular vesicles as therapeutic delivery systems
From: Extracellular Vesicles for Drug Delivery in Cancer Treatment
NCT number | Phase | Condition | Source of EVs | Cargo |
|---|---|---|---|---|
NCT04592484 | Phase I/II | Advanced solid tumours | HEK293 | STING agonist |
NCT03608631 | Phase I | Pancreatic cancer | Mesenchymal stromal cells | KRAS-G12D small interfering RNA |
NCT01294072 | Phase I | Colon cancer | Plant | Curcumin |
NCT01854866 | Phase II | Malignant pleural effusion | Tumour cells | Chemotherapy |
NCT02657460 | Phase II | Malignant pleural effusion | Tumour cells | Methotrexate |
NCT01159288 | Phase II | Non-small cell lung cancer | Dendritic cells | Peptides |
NCT01668849 | Phase I | Head and neck cancer | Plant | fentanyl patch |
NA | Phase I | Melanoma | Autologous monocyte-derived dendritic cells | MAGE3 |
NA | Phase I | Lung cancer | A549 | Cisplatin |